One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
https://doi.org/10.1136/jitc-2020-sitc2020.0434
Copy DOI
Export
Save
Share
Cite Journal: Journal for ImmunoTherapy of Cancer |  Publication Date: Nov 1, 2020 |
 Citations: 7 |  License type: CC BY-NC 4.0 |
Affiliation: Memorial Sloan Kettering Cancer Center, Infinity Pharmaceuticals (United States), Emory University Hospital, Massachusetts General Hospital, University of California, Los Angeles, Epizyme (United States), The University of Texas MD Anderson Cancer Center, University of California, San Diego, Infinity (United States), Hackensack University Medical Center
BackgroundEganelisib is a first-in-class, oral, selective PI3K-γ inhibitor. Preclinically, eganelisib reprograms macrophages/myeloid derived suppressor cells (MDSCs) from an immune-suppressive to an immune-activating phenotype and enhances efficacy of checkpoint inhibitors. Efficacy...
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
